GSK discontinues Beano claim
This article was originally published in The Tan Sheet
GlaxoSmithKline Consumer Healthcare disagrees with the Electronic Retailing Self-Regulation Program's determination that the firm failed to support an exclusivity claim for its Beano supplement, but will qualify the claim in future ads, the firm says. The Council of Better Business Bureaus arm's inquiry was conducted after an anonymous competitor complained about a statement on Beano's Web site. The claim, "The only product available that can help prevent gas," was discontinued during the review, but GSK reserved the right to use the statement in future advertising. It defended its position with literature and noted Beano's biggest competitors, including Gas-X, relieve rather than prevent gas. However, ERSP determined the evidence was insufficient in showing that competing products were "ineffective in preventing gas" and that the statement was therefore inaccurate...
You may also be interested in...
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."